Long-term efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis who had failed or were intolerant to oral nonsteroidal immunosuppressants: pooled analysis of JADE clinical trials

被引：0
|
作者：
Ardern-Jones, M. [1 ]
Ameen, M. [2 ]
de Bruin-Weller, M. [3 ]
Simpson, E. [4 ]
Chiu, W. S. [5 ]
Biswas, P. [6 ]
Chan, G. [7 ]
Koulias, C. [8 ]
Weidinger, S. [9 ]
机构：
[1] Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England
[2] Royal Free London Natl Hlth Serv Fdn Trust, London, England
[3] Univ Med Ctr Utrecht, Utrecht, Netherlands
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Pfizer Ltd, Surrey, England
[6] Pfizer Inc, New York, NY USA
[7] Pfizer Inc, Groton, CT 06340 USA
[8] Pfizer Hellas SA, Athens, Greece
[9] Univ Hosp Schleswig Holstein, Kiel, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
642
引用
收藏
页码：E151 / E152
页数：2
相关论文
共 50 条
  • [21] Protocol for an ongoing, phase III multicentre, long-term extension study investigating the long-term safety and efficacy of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE EXTEND)
    Simpson, E. L.
    Reich, K.
    Silverberg, J. I.
    Nasir, A.
    Criado, P. R.
    Biswas, P.
    Koppensteiner, H.
    Fan, D.
    Rojo, R.
    Farooqui, S. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E159 - E159
  • [22] SHORT-TERM EFFICACY AND SAFETY OF ABROCITINIB BY BASELINE DISEASE SEVERITY IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Rice, Zakiya P.
    Gooderham, Melinda J.
    Lebwohl, Mark G.
    Simpson, Eric L.
    Boguniewicz, Mark
    Wollenberg, Andreas
    Lazariciu, Irina
    Chan, Gary L.
    Alderfer, Justine
    Watkins, Melissa
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 30 - 30
  • [23] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial
    Li, Hang
    Cheng, Hao
    Lu, Qianjin
    Lai, Wei
    Tao, Xiaohua
    Encinas, Gerardo A.
    Vyas, Shefali
    Wang, Bo
    Luo, Xin
    Li, Shiqi
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [24] Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
    Fadlalmola, Hammad Ali
    Albadrani, Muayad Saud
    Elhusein, Amal Mohamed
    Mohamedsalih, Wahieba E.
    Swamy, Veerabhadra D. S.
    Mamanao, Daniel Mon
    DERMATOLOGY RESEARCH AND PRACTICE, 2021, 2021
  • [25] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III JADE MONO-2 study
    Silverberg, J.
    Simpson, E. L.
    Thyssen, J. P.
    Gooderham, M.
    Chan, G.
    Feeney, C.
    Biswas, P.
    Valdez, H.
    DiBonaventura, M.
    Nduaka, C.
    Rojo, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E100 - E100
  • [26] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [27] Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
    Eichenfield, Lawrence
    Flohr, Carsten
    Sidbury, Robert
    Szalai, Zsuzsanna
    Galus, Ryszard
    Yao, Zhirong
    Takahashi, Hidetoshi
    Barbarot, S. Ebastien
    Feeney, Claire
    Zhang, Fan
    DiBonaventura, Marco
    Rojo, Ricardo
    Valdez, Hernan
    Chan, Gary
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB146 - AB146
  • [28] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [29] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study
    Simpson, E. L.
    Sinclair, R.
    Forman, S.
    Wollenberg, A.
    Asch, R.
    Cork, M.
    Bieber, T.
    Thyssen, J. P.
    Yosipovitch, G.
    Magnolo, N.
    Maari, C.
    Flohr, C.
    Feeney, C.
    Biswas, P.
    Tatulych, S.
    Valdez, H.
    Rojo, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E105 - E106
  • [30] Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND
    Simpson, Eric
    Paller, Amy
    Wollenberg, Andreas
    Bewley, Anthony
    Cork, Michael
    Hong, Chih-Ho
    Soong, Weily
    Almgren, Peter
    Carlsson, Anna
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB190 - AB190
12345